Viridian (VRDN) COO granted 176,550 options and 35,300 RSUs, with RSUs vesting

Rhea-AI Filing Summary

Viridian Therapeutics Chief Operating Officer Thomas W. Beetham reported multiple equity award transactions. On March 2, 2026, he received a stock option grant for 176,550 shares vesting in 48 equal monthly installments, and 35,300 Restricted Stock Units (RSUs) vesting 25% annually over four years.

On March 3, 2026, 9,409 RSUs converted into the same number of common shares, and 3,138 common shares were disposed of at $29.32 per share to cover tax obligations. Following these transactions, he directly held 13,271 common shares and 28,227 RSUs.

Insights

Equity Compensation Analyst

Routine equity grants and vesting activity with tax withholding; overall impact is neutral.

Viridian Therapeutics’ Chief Operating Officer received substantial new equity awards, including 176,550 stock options and 35,300 RSUs. These awards vest over several years, aligning his compensation with long-term company performance rather than immediate cash.

The March 3, 2026 RSU conversion added 9,409 common shares, while 3,138 shares were withheld at $29.32 per share to satisfy taxes. This withholding is a common administrative mechanism and not an open-market sale. The filing mainly updates Beetham’s equity position and is not thesis-changing.

Insider Trade Summary

9,409 shares exercised/converted

Mixed 5 txns

Insider Beetham Thomas W.

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	9,409	$0.00	--
Exercise	Common Stock	9,409	$0.00	--
Tax Withholding	Common Stock	3,138	$29.32	$92K
Grant/Award	Stock Option (Right to Buy)	176,550	$0.00	--
Grant/Award	Restricted Stock Units	35,300	$0.00	--

Holdings After Transaction: Restricted Stock Units — 28,227 shares (Direct); Common Stock — 16,409 shares (Direct); Stock Option (Right to Buy) — 176,550 shares (Direct)

Footnotes (1)

1. The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date. Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beetham Thomas W.

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		9,409	A	(2)	16,409(5)	D
Common Stock	03/03/2026		F		3,138	D	$29.32	13,271(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.25	03/02/2026		A		176,550		(1)	03/02/2036	Common Stock	176,550	$0	176,550	D
Restricted Stock Units	(2)	03/02/2026		A		35,300		(3)	(3)	Common Stock	35,300	$0.00	35,300	D
Restricted Stock Units	(2)	03/03/2026		M			9,409	(4)	(4)	Common Stock	9,409	$0.00	28,227	D

Explanation of Responses:

1. The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

2. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

3. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

4. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

5. Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

	Jennifer Tousignant, Attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Viridian Therapeutics (VRDN) COO Thomas W. Beetham receive?

Thomas W. Beetham received a stock option grant for 176,550 shares and 35,300 Restricted Stock Units (RSUs) on March 2, 2026. The options vest monthly over four years, while the RSUs vest 25% annually over four years, subject to continued service.

How do the new Viridian Therapeutics (VRDN) stock options granted to the COO vest?

The 176,550 stock options granted to the COO vest in 48 equal monthly installments following March 2, 2026. Each month, a portion becomes exercisable, contingent on his continued service with Viridian Therapeutics during each vesting date over the four-year period.

What are the vesting terms for the new RSUs reported by Viridian Therapeutics (VRDN)?

The 35,300 RSUs granted on March 2, 2026 vest over four years, with 25% vesting on each yearly anniversary of the grant date. Each RSU represents a contingent right to receive one share of Viridian Therapeutics common stock upon vesting.

What happened when Viridian Therapeutics (VRDN) RSUs converted on March 3, 2026?

On March 3, 2026, 9,409 Restricted Stock Units converted into 9,409 shares of Viridian Therapeutics common stock. In a related transaction, 3,138 common shares were disposed of at $29.32 per share to cover tax liabilities associated with the RSU vesting.

Did the Viridian Therapeutics (VRDN) COO sell shares in the open market in this Form 4?

The Form 4 shows a disposition of 3,138 common shares at $29.32 per share coded as “F,” meaning they were used to pay tax liabilities. This is a tax-withholding disposition, not an open-market sale initiated for portfolio or valuation reasons.

How many Viridian Therapeutics (VRDN) shares does the COO own after these transactions?

After the reported transactions, the COO directly holds 13,271 shares of Viridian Therapeutics common stock and 28,227 Restricted Stock Units. He also holds 176,550 stock options and 35,300 newly granted RSUs that will vest over future years if service continues.